THE MICROVASCULAR TRUTH

MODULE 5: THE MICROVASCULAR TRUTH, 25 Entries (Articles 101–125)

Module Frame: The standard model of heart disease, cholesterol, plaque, blockage, heart attack, was built from men’s disease. Women’s coronary artery disease frequently follows a different and more dangerous path: non-obstructive coronary arteries, microvascular dysfunction, plaque erosion rather than rupture, spontaneous dissection, coronary vasospasm. These patterns were not in the standard cardiology textbooks of 1990. They are in the literature of 2024. This module gives women, and their physicians, the full picture.

101. MINOCA: When the Heart Attack Has Normal Arteries

Slug: /women/minoca-heart-attack-normal-arteries-women Status: Net-new (M5 anchor) Source asset: net-new, M5 anchor Module: M5, The Microvascular Truth

Why it matters: MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries) accounts for approximately 6-15% of all MI presentations, and 61% of MINOCA patients are female. Women with MINOCA are frequently told “your arteries look fine” and sent home without treatment or follow-up, despite similar mortality rates to obstructive MI. This is one of the most urgent clinical equity issues in cardiology.

Hook: “Her troponin was elevated. Her angiogram was clean. She was told to go home. Her cardiologist at the academic center reviewed the case eight months later: MINOCA. She had had a real heart attack. Nobody told her.”

Core objective: Defines MINOCA, covers the multiple etiologies (myocarditis, plaque erosion, vasospasm, SCAD, coronary embolism, stress cardiomyopathy), explains why cardiac MRI is essential for MINOCA workup, gives the evidence on MINOCA outcomes, and empowers women to advocate for complete evaluation.

The 5 Core Questions:

1. Q: “What is MINOCA and why does it happen?” A: MINOCA is a myocardial infarction (elevated troponin + ischemic ECG changes or wall motion abnormality) in the absence of obstructive coronary artery disease (no stenosis above 50% on angiography). It is not a single disease but a clinical presentation with multiple possible underlying etiologies. (5/Solid)
2. Q: “What causes MINOCA?” A: Major etiologies: plaque erosion or rupture with spontaneous resolution; coronary vasospasm (Prinzmetal’s angina); SCAD (spontaneous coronary artery dissection) missed on angiography; coronary embolism; myocarditis (mimicking MI); microvascular obstruction or dysfunction; and Takotsubo cardiomyopathy. Cardiac MRI identifies the etiology in 70-80% of MINOCA cases. (5/Solid)
3. Q: “Why are 61% of MINOCA patients female?” A: Multiple contributing factors: plaque erosion (rather than rupture) is the predominant mechanism in younger women; coronary vasospasm and microvascular dysfunction are more prevalent in women; SCAD is predominantly female; Takotsubo is 88.9% female. The MINOCA spectrum maps closely to female-specific cardiac pathology. (5/Solid)
4. Q: “What is the prognosis of MINOCA?” A: Similar one-year mortality to obstructive MI, approximately 2-5%, which is higher than many clinicians assume when they say “your arteries look fine.” Guideline-directed medical therapy (statin, aspirin, ACE inhibitor, beta-blocker) improves outcomes in MINOCA, particularly for the plaque-related and inflammatory etiologies. (5/Solid)
5. Q: “What should happen after a MINOCA diagnosis?” A: Complete workup: cardiac MRI (within days to weeks); provocative testing for vasospasm if appropriate; hypercoagulable panel if coronary embolism suspected; echocardiography; and follow-up with a cardiologist experienced in MINOCA, ideally at an academic center. Do not accept discharge without a workup plan. (5/Solid)

Key clinical anchors:

• Tamis-Holland JE et al., MINOCA: AHA scientific statement, Circulation 2019, DOI 10.1161/CIR.0000000000000670
• Collet JP et al., ESC NSTEMI guidelines, EHJ 2021
• Reynolds HR et al., mechanisms of MINOCA, JACC 2016, DOI 10.1016/j.jacc.2016.06.017

Mandatory cross-links: cardiac-mri-women-diagnosis, scad-spontaneous-coronary-artery-dissection-women, takotsubo-broken-heart-syndrome-women, coronary-vasospasm-women, microvascular-angina-women

Production notes: The “troponin elevated, clean angiogram, sent home” scenario is the core public health message. This is the M5 anchor. Clinical precision essential. Word count: 3,000.

Virality/Buying signal:

• Share potential: High
• Buy potential: High

102. SCAD: Spontaneous Coronary Artery Dissection, Why 1 in 3 Young Women’s Heart Attacks Is This

Slug: /women/scad-spontaneous-coronary-artery-dissection-women Status: Net-new (M5 core) Source asset: net-new, M5 core Module: M5, The Microvascular Truth

Why it matters: SCAD is the cause of 35% of myocardial infarctions in women under 50, making it not a rare condition but the leading cause of MI in young women. It is neither well-known to most women nor to many general cardiologists. Mismanagement (stenting a dissection) makes it worse. The SCAD community has built extraordinary patient advocacy; the clinical content should reflect that.

Hook: “At 41, she had a heart attack. No plaque. No clot. The coronary artery had torn itself. It is called SCAD. It causes more heart attacks in young women than any other diagnosis. Most women have never heard of it.”

Core objective: Full SCAD explainer, pathophysiology, demographics, recognition, management (conservative vs. interventional), associated conditions (FMD, connective tissue disorders), recurrence risk, psychological impact, and patient community resources.

The 5 Core Questions:

1. Q: “What is SCAD and how is it different from a plaque heart attack?” A: In a standard heart attack, cholesterol plaque ruptures and a clot forms. In SCAD, the coronary artery wall itself tears, creating a false lumen that compresses the true lumen and causes ischemia. There is no plaque, no clot, no blockage. The artery is structurally tearing. (5/Solid)
2. Q: “Who gets SCAD?” A: 80-95% female, mean age 44. Not the classic cardiovascular risk factor profile, most SCAD patients have few traditional risk factors. Associated with: physical or emotional stress event prior to SCAD; peripartum period (20-25% of cases); connective tissue disorders (Marfan, Ehlers-Danlos); fibromuscular dysplasia (50-80% of cases). (5/Solid)
3. Q: “Why is stenting dangerous in SCAD?” A: In plaque-rupture MI, stenting opens a blocked artery. In SCAD, the artery wall is already fragile; wire passage and balloon inflation can extend the dissection or cause complete occlusion of the vessel. Conservative management (anticoagulation, observation, allow natural healing) is preferred in hemodynamically stable patients. (5/Solid)
4. Q: “What is the SCAD recurrence rate?” A: Approximately 14% at 5 years, meaning 1 in 7 SCAD survivors will have another event. This is substantially higher than for plaque-rupture MI. Long-term follow-up with SCAD-experienced cardiologists and annual imaging protocols are recommended. (5/Solid)
5. Q: “What is fibromuscular dysplasia and should I be screened for it?” A: FMD is a non-inflammatory arterial disease causing beaded or irregular arterial walls, present in 50-80% of SCAD patients. It primarily affects renal and carotid/vertebral arteries, with significant implications for renovascular hypertension and stroke risk. CTA of renal and carotid arteries is recommended for all SCAD patients. (5/Solid)

Key clinical anchors:

• Hayes SN et al., SCAD, Nat Rev Dis Primers 2024, DOI 10.1038/s44325-024-00004-y
• Saw J et al., SCAD clinical features and outcomes, JACC 2019, DOI 10.1016/j.jacc.2018.11.034
• Adlam D et al., SCAD and connective tissue disease, EHJ 2019

Mandatory cross-links: minoca-heart-attack-normal-arteries-women, scad-pregnancy-postpartum, fibromuscular-dysplasia-women-cardiac, cardiac-mri-women-diagnosis, women-heart-attack-symptoms-different

Production notes: Use the 35% statistic as the lead. The physical stress event trigger, peripartum association, and FMD connection are essential. Patient community reference: SCAD Alliance (scadalliance.org). Word count: 3,000.

Virality/Buying signal:

• Share potential: High
• Buy potential: Medium

103. Microvascular Angina in Women: Chest Pain When the Big Arteries Are Fine

Slug: /women/microvascular-angina-women Status: Net-new (M5 core) Source asset: net-new, M5 core Module: M5, The Microvascular Truth

Why it matters: Coronary microvascular dysfunction (CMD), impaired function of the small coronary vessels that cannot be seen on standard angiography, is present in approximately 50-60% of women who undergo catheterization for chest pain with non-obstructive coronaries. It causes real, limiting angina, increased cardiac events, and reduced quality of life. It was not accepted as a real diagnosis until the WISE study in 2006.

Hook: “She had chest pain with exertion for three years. Two catheterizations showed clean arteries. Three cardiologists told her it was anxiety. The WISE study from 2006 has a name for this: coronary microvascular dysfunction. She had a real diagnosis.”

Core objective: Explains coronary microvascular dysfunction, covers the WISE study’s pivotal contribution, reviews diagnostic testing (coronary flow reserve, invasive physiological testing, stress cardiac MRI), covers treatment options (ranolazine, guideline-directed therapy), and validates CMD as a real and serious cardiac diagnosis.

The 5 Core Questions:

1. Q: “What is coronary microvascular dysfunction?” A: CMD is impaired function of the coronary microcirculation, the small arterioles and capillaries (too small to see on angiography) that account for over 90% of coronary vascular resistance. In CMD, these vessels fail to dilate appropriately during exercise or stress, causing ischemia despite normal large-vessel anatomy. (5/Solid)
2. Q: “What is the WISE study and why did it matter?” A: The Women’s Ischemia Syndrome Evaluation (WISE) study demonstrated that women with chest pain and non-obstructive coronaries had real ischemia, real microvascular dysfunction, and real adverse cardiac outcomes (including MI and death), disproving the belief that non-obstructive coronary findings in women were benign. (5/Solid, Bairey Merz CN et al., JACC 2006)
3. Q: “How is CMD diagnosed?” A: The gold standard is invasive physiological testing (coronary flow reserve and microvascular resistance measurements with adenosine or acetylcholine during cardiac catheterization). Non-invasive alternatives: stress cardiac MRI (subendocardial perfusion defects), PET myocardial perfusion imaging (most sensitive non-invasive method). (5/Solid)
4. Q: “What are the treatment options for CMD?” A: Ranolazine (anti-anginal, improves microvascular function in CMD); ACE inhibitors (improve endothelial function); beta-blockers for rate control; statins (independent vascular benefits); aggressive treatment of underlying risk factors (especially hypertension, insulin resistance, inflammation); and lifestyle (exercise training improves coronary flow reserve measurably). (5/Solid)
5. Q: “Does CMD affect mortality?” A: Yes, women with CMD have higher rates of major adverse cardiovascular events over time compared to women with normal microvascular function. The five-year event rate for women with CMD is not benign, it is comparable in many studies to obstructive CAD. CMD requires active treatment and surveillance, not reassurance. (5/Solid)

Key clinical anchors:

• Bairey Merz CN et al., WISE study, JACC 2006, DOI 10.1016/j.jacc.2005.01.072
• Camici PG et al., coronary microvascular dysfunction, EHJ 2016, DOI 10.1093/eurheartj/ehv282
• Tamis-Holland JE et al., MINOCA, Circulation 2019, DOI 10.1161/CIR.0000000000000670

Mandatory cross-links: minoca-heart-attack-normal-arteries-women, anoca-angina-normal-coronary-arteries, coronary-vasospasm-women, cardiac-mri-women-diagnosis, chest-pain-anxiety-vs-cardiac-women

Production notes: The WISE study is the cardinal reference. The “three cardiologists, anxiety diagnosis, real diagnosis” narrative is accurate and powerful. Word count: 2,800.

Virality/Buying signal:

• Share potential: High
• Buy potential: High

104. ANOCA: Angina with Normal Coronary Arteries, Understanding the New Diagnosis

Slug: /women/anoca-angina-normal-coronary-arteries Status: Net-new (M5 core) Source asset: net-new, M5 core Module: M5, The Microvascular Truth

Why it matters: ANOCA (Angina with Non-Obstructive Coronary Arteries) is the current clinical term encompassing both vasospastic angina and microvascular angina in patients with non-obstructive coronary disease. Up to 50% of patients referred for cardiac catheterization for angina have no obstructive disease, and ANOCA provides a diagnostic framework for this large and predominantly female population.

Hook: “The term ANOCA was not in her cardiologist’s training. But the condition she had been living with for four years very much existed. The nomenclature changed. The disease always was real.”

Core objective: Explains ANOCA as the unifying clinical framework, distinguishes vasospastic from microvascular subtypes, covers diagnostic protocols (functional angiography with provocative testing), and reviews guideline-recommended treatment by ANOCA subtype.

The 5 Core Questions:

1. Q: “What is ANOCA and how is it defined?” A: ANOCA is a clinical syndrome of chest pain (angina) in the absence of obstructive coronary artery disease (stenosis below 50%). It is an umbrella term encompassing: (1) coronary vasospastic angina (CVA); (2) microvascular angina (MVA, impaired coronary flow reserve/microvascular resistance); and (3) mixed pattern. (5/Solid)
2. Q: “What proportion of ANOCA patients are women?” A: Women represent the majority of ANOCA patients, approximately 60-70% in most registry data. The underlying biology (microvascular dysfunction, vasomotor dysregulation, higher vasospasm prevalence) closely tracks female-specific vascular physiology. (5/Solid)
3. Q: “How is ANOCA subtype determined?” A: Functional coronary angiography using: (1) adenosine or acetylcholine for coronary flow reserve measurement (CFR) and index of microvascular resistance (IMR); (2) acetylcholine provocative testing for vasospasm. CFR below 2.5 or elevated IMR defines microvascular angina; epicardial spasm on acetylcholine challenge defines vasospastic angina. (5/Solid)
4. Q: “How is vasospastic angina treated?” A: Calcium channel blockers (diltiazem, amlodipine) are first-line, they prevent coronary smooth muscle spasm. Long-acting nitrates for breakthrough symptoms. Avoid triggers: cold, emotional stress, cocaine (strong vasospasm trigger), tobacco. Beta-blockers may paradoxically worsen vasospasm. (5/Solid)
5. Q: “What is the prognosis of ANOCA?” A: Better than obstructive CAD overall, but not benign, particularly for the vasospastic subtype which carries risks of life-threatening arrhythmia (ventricular fibrillation from ischemia) and MI in severe cases. Microvascular angina significantly impairs quality of life and has modest increases in adverse events at long-term follow-up. (4/Solid)

Key clinical anchors:

• Kunadian V et al., ANOCA diagnosis and management, EHJ 2020, DOI 10.1093/eurheartj/ehaa271
• Bairey Merz CN et al., WISE study, JACC 2006, DOI 10.1016/j.jacc.2005.01.072
• Pepine CJ et al., coronary microvascular disease in women, Int J Cardiol 2015

Mandatory cross-links: microvascular-angina-women, coronary-vasospasm-women, minoca-heart-attack-normal-arteries-women, cardiac-mri-women-diagnosis, chest-pain-anxiety-vs-cardiac-women

Production notes: The “term didn’t exist, condition always did” framing is historically accurate. This piece helps patients with ANOCA find language for their experience. Word count: 2,500.

Virality/Buying signal:

• Share potential: High
• Buy potential: Medium

105. Coronary Vasospasm in Women: The Heart Attack That Comes and Goes

Slug: /women/coronary-vasospasm-women Status: Net-new (M5 core) Source asset: net-new, M5 core Module: M5, The Microvascular Truth

Why it matters: Coronary vasospasm (Prinzmetal’s angina, variant angina) is dramatically underdiagnosed in women, causing chest pain that is typically nocturnal or at rest, not with exertion, and may be completely absent on a standard stress test. Vasospastic angina can cause MI, dangerous arrhythmia, and sudden cardiac death, in women who have been told their arteries are normal.

Hook: “She woke at 3 AM with crushing chest pain for ten minutes that resolved completely. Stress test: normal. Catheterization: normal. Her cardiologist at the academic center said: did anyone challenge your arteries? No one had. Acetylcholine test: severe vasospasm, immediate ischemia. Her arteries were normal. Her arteries were the problem.”

Core objective: Explains coronary vasospasm mechanism, covers the specific triggers and clinical patterns, explains why standard stress testing misses it, covers the acetylcholine provocative test, and provides complete management guidance.

The 5 Core Questions:

1. Q: “What is coronary vasospasm and what triggers it?” A: Coronary vasospasm is focal, reversible, severe constriction of a coronary artery causing ischemia without plaque rupture. Triggers: cold exposure, hyperventilation, emotional stress, cocaine, methamphetamine, tobacco, and paradoxically, some medications including 5-fluorouracil (chemotherapy). It typically occurs at rest, often at night. (5/Solid)
2. Q: “Why does a standard stress test miss vasospasm?” A: Stress tests are designed to unmask atherosclerotic narrowing, insufficient blood flow at peak exercise demand. Vasospasm occurs spontaneously at rest or in response to specific triggers, not predictably at maximum exertion. An exercise stress test is largely blind to vasospastic disease. (5/Solid)
3. Q: “How is vasospasm diagnosed?” A: Provocative testing during cardiac catheterization, intracoronary acetylcholine or ergonovine induces spasm in susceptible vessels, which is directly visualized and simultaneously correlated with ECG and symptoms. This test is underperformed in the US but routine in Japan where vasospasm is most intensively studied. (5/Solid)
4. Q: “What are the dangerous complications of undiagnosed vasospasm?” A: Sustained vasospasm can cause MI (troponin-positive) and life-threatening ventricular arrhythmia (VF from ischemia). Sudden cardiac death from vasospasm, while uncommon, is reported. Women with unexplained syncope, nocturnal chest pain, or unexplained ventricular arrhythmia should be evaluated for vasospasm. (5/Solid)
5. Q: “What is the treatment for coronary vasospasm?” A: Calcium channel blockers (diltiazem or amlodipine) as first-line, very effective for most patients. Long-acting nitrates for breakthrough episodes. Trigger avoidance (cold, cigarettes, cocaine). Magnesium supplementation may reduce spasm frequency in deficient patients. ICD implantation in patients with prior VF from vasospasm. (5/Solid)

Key clinical anchors:

• Beltrame JF et al., coronary vasospasm, Circ Cardiovasc Qual Outcomes 2015
• JCS Joint Working Group, coronary vasospasm guidelines, Circ J 2014
• Phan D et al., coronary vasospasm and sex differences, JACC 2021

Mandatory cross-links: anoca-angina-normal-coronary-arteries, microvascular-angina-women, minoca-heart-attack-normal-arteries-women, chest-pain-anxiety-vs-cardiac-women, cardiac-mri-women-diagnosis

Production notes: The 3 AM nocturnal chest pain narrative is the diagnostic flag most women miss. The “arteries were normal; arteries were the problem” paradox is the clinical core. Word count: 2,500.

Virality/Buying signal:

• Share potential: High
• Buy potential: Medium

106. HFpEF: The Heart Failure Women Get That Nobody Talks About

Slug: /women/hfpef-heart-failure-preserved-ejection-fraction-women Status: Net-new (M5 critical) Source asset: net-new, M5 critical Module: M5, The Microvascular Truth

Why it matters: HFpEF (Heart Failure with Preserved Ejection Fraction) is the dominant heart failure syndrome in women, with 2:1 female predominance and 2.8x higher odds of HFpEF over HFrEF in women. It is driven by arterial stiffness, diastolic dysfunction, and metabolic syndrome, exactly the conditions that accelerate at menopause. Treatment for HFpEF has historically lagged HFrEF, but SGLT2 inhibitors and GLP-1 agonists are changing that.

Hook: “She could not walk to the mailbox without stopping to catch her breath. Her ejection fraction was 58%. ‘Normal,’ the report said. Her cardiologist said: normal ejection fraction does not mean normal heart. You have heart failure. A different kind.”

Core objective: Explains HFpEF mechanism (diastolic dysfunction, impaired relaxation, elevated filling pressures), covers the sex-specific epidemiology, explains why symptoms in HFpEF are as debilitating as HFrEF, reviews current treatment options (SGLT2 inhibitors, GLP-1 agonists, exercise), and addresses HFpEF in perimenopausal women.

The 5 Core Questions:

1. Q: “What is HFpEF and why does ejection fraction say ‘normal’?” A: HFpEF is heart failure in which the left ventricle contracts normally (EF above 50%) but fails to relax adequately (diastolic dysfunction). The heart fills less efficiently, leaving pressures elevated and causing the same symptoms as HFrEF, dyspnea, edema, exercise intolerance, with a “normal” pump function by ejection fraction. EF is a measure of squeezing; HFpEF is a failure of relaxing. (5/Solid)
2. Q: “Why is HFpEF predominantly a women’s disease?” A: Multiple converging factors: post-menopausal arterial stiffening (major diastolic dysfunction driver); microvascular inflammation from metabolic syndrome; greater systemic inflammation per unit of metabolic burden; higher hypertension incidence in older women; and possibly direct estrogen-loss effects on myocardial compliance. Women have 2.8x higher odds of developing HFpEF over HFrEF compared to men. (5/Solid, PMC9720805)
3. Q: “What treatments are now supported for HFpEF?” A: SGLT2 inhibitors (empagliflozin, EMPEROR-Preserved; dapagliflozin, DELIVER) reduce HF hospitalizations and cardiovascular death in HFpEF, the first therapies to show outcome benefit. GLP-1 agonists (semaglutide, STEP-HFpEF) improve symptoms and exercise capacity in obese HFpEF. Exercise training improves peak VO2 measurably. (5/Solid)
4. Q: “Is HFpEF a fatal condition?” A: Yes, five-year mortality in HFpEF is approximately 50-60%, comparable to many cancers. However, most of the excess mortality is cardiovascular (sudden death, progression to low-EF failure) and is addressable with currently available therapies. HFpEF is not a benign “normal EF” situation. (5/Solid)
5. Q: “What should a woman with HFpEF monitor?” A: Daily weight (rise of 2+ lbs overnight signals fluid retention requiring immediate attention); daily blood pressure; symptom progression (lower extremity edema, orthopnea, worsening dyspnea); regular BNP/NT-proBNP; echocardiography at 6-12 month intervals; and optimization of all underlying conditions (BP control, diabetes, obesity, sleep apnea). (5/Practical)

Key clinical anchors:

• Anand IS et al., sex differences in HFpEF, JACC 2018, PMC9720805
• Anker SD et al., EMPEROR-Preserved trial, NEJM 2021, DOI 10.1056/NEJMoa2107038
• Kosiborod MN et al., STEP-HFpEF trial, NEJM 2023, DOI 10.1056/NEJMoa2306963

Mandatory cross-links: heart-failure-preserved-ejection-fraction-women, perimenopause-cardiovascular-risk, metabolic-syndrome-women-explained, sleep-apnea-women-cardiac-risk, glp1-medications-women-cardiovascular-evidence

Production notes: The “relaxing failure vs. squeezing failure” explanation is the key patient education framing. SGLT2 inhibitors and GLP-1 agonists are the current therapy story. Word count: 3,000.

Virality/Buying signal:

• Share potential: High
• Buy potential: High

107. Plaque Erosion vs. Plaque Rupture: Why Women’s Heart Attacks Look Different Under the Microscope

Slug: /women/plaque-erosion-vs-rupture-women Status: Net-new (M5 core) Source asset: net-new, M5 mechanism Module: M5, The Microvascular Truth

Why it matters: The classic heart attack mechanism is plaque rupture, a vulnerable plaque cap fractures, exposing thrombogenic material, and a clot forms. In younger women, the predominant mechanism is plaque erosion, no cap rupture, but the plaque surface erodes, triggering clot formation over intact fibrous cap. These different mechanisms have different risk factor profiles and potentially different treatment implications.

Hook: “The pathologist said: this is plaque erosion, not rupture. Her arteries were not the arteries we teach in medical school. They were the arteries women have. And the cardiology curriculum had not caught up.”

Core objective: Explains plaque erosion biology vs. plaque rupture biology, covers the evidence that erosion is more prevalent in younger and premenopausal women, discusses implications for anticoagulation vs. antiplatelet therapy, and explores the EROSION trial findings.

The 5 Core Questions:

1. Q: “What is plaque erosion and how is it different from rupture?” A: Plaque rupture: a thin-cap fibroatheroma physically fractures, exposing lipid core, highly thrombogenic. Plaque erosion: the fibrous plaque cap remains intact but the endothelial surface erodes, a smaller inflammatory event triggers a clot over the intact but denuded cap. No cap fracture, no lipid core exposure. (5/Solid)
2. Q: “Who is more likely to have plaque erosion vs. rupture?” A: Erosion predominates in: women under 50, smokers, people with smaller plaque burden, and those with high baseline inflammatory markers. Rupture predominates in: older patients, men, those with large lipid-rich plaque burden and high LDL. The shift toward erosion in younger women may explain their different risk factor profiles and different statin response. (5/Solid)
3. Q: “Is there a diagnostic way to distinguish erosion from rupture acutely?” A: Optical coherence tomography (OCT), an intravascular imaging technique, can visualize plaque surface morphology and distinguish erosion from rupture during catheterization. OCT use is growing in MINOCA workup protocols precisely because of this capability. (5/Solid)
4. Q: “What are the treatment implications of plaque erosion?” A: Plaque erosion may respond differently to anticoagulation vs. antiplatelet therapy. The EROSION trial explored dissolving erosion-based thrombus with anticoagulation alone (without stenting), with promising results. This is an evolving area with direct implications for MINOCA management in younger women. (4/Evolving)
5. Q: “Does smoking specifically drive plaque erosion in women?” A: Yes, tobacco smoking is the strongest independent driver of plaque erosion, far more than LDL level. Young women who smoke are specifically at risk for erosion-based MI, which partly explains the disproportionate MI risk of smoking in young women. This is a compelling smoking cessation argument for young women. (5/Solid)

Key clinical anchors:

• Libby P, plaque erosion and rupture, NEJM 2021, DOI 10.1056/NEJMra2104882
• Jia H et al., EROSION trial, EHJ 2019, DOI 10.1093/eurheartj/ehz201
• Stone GW et al., plaque erosion and women, JACC 2018

Mandatory cross-links: minoca-heart-attack-normal-arteries-women, scad-spontaneous-coronary-artery-dissection-women, smoking-women-cardiovascular-risk, women-heart-attack-symptoms-different, microvascular-angina-women

Production notes: “The arteries we teach in medical school” vs. “the arteries women have”, this is exactly the register of intellectual honesty that defines Mogire’s voice. Word count: 2,500.

Virality/Buying signal:

• Share potential: High
• Buy potential: Low

108. Takotsubo Cardiomyopathy: Broken Heart Syndrome Is a Real Cardiac Emergency

Slug: /women/takotsubo-broken-heart-syndrome-women Status: Adapted Source asset: deep_dive_takotsubo.md (if exists) / net-new Module: M5, The Microvascular Truth

Why it matters: Takotsubo cardiomyopathy (“broken heart syndrome”) is a transient acute LV dysfunction triggered by emotional or physical stress, 88.9% female, typically post-menopausal. It mimics an anterior MI with chest pain, ST elevation, and wall motion abnormality, but resolves over days to weeks with no permanent damage in most cases. It is not benign: in-hospital complication rates rival STEMI and it recurs in 10-15% of cases.

Hook: “She lost her husband in the morning. By evening, she was in the catheterization laboratory with ST elevation and severe wall motion abnormality. The angiogram showed perfect arteries. Her heart was broken. Literally.”

Core objective: Explains Takotsubo mechanism (catecholamine surge and estrogen-depleted myocardium), covers epidemiology (88.9% female, mean age 67), management (supportive, anticoagulation for LV thrombus), complications (cardiogenic shock, arrhythmia, LV outflow tract obstruction), and recurrence.

The 5 Core Questions:

1. Q: “What causes Takotsubo cardiomyopathy?” A: An intense physical or emotional stressor (or both) triggers a massive catecholamine surge, which in the estrogen-depleted post-menopausal myocardium causes direct catecholamine cardiotoxicity, temporarily stunning the apical LV while the base continues contracting normally. The apical ballooning creates the classic octopus-trap (“tako-tsubo”) appearance on echocardiography. (5/Solid)
2. Q: “Why is Takotsubo almost exclusively post-menopausal women?” A: Estrogen protects myocardial receptors from catecholamine-induced cardiotoxicity. In the estrogen-replete state, catecholamine surges are tolerated. Post-menopause, loss of this protection makes the myocardium uniquely vulnerable to the same catecholamine surges that younger women tolerate without cardiac consequence. (5/Solid)
3. Q: “Is Takotsubo dangerous?” A: Yes, in-hospital complication rates approach 10-20%, including cardiogenic shock (4-6%), LV thrombus with stroke risk (3%), arrhythmia, LV outflow tract obstruction (rare but dangerous). The 2015 NEJM registry found in-hospital mortality of 4%, comparable to non-STEMI. It is not simply a psychiatric diagnosis with a cardiac manifestation. (5/Solid, Templin C et al. NEJM 2015)
4. Q: “How is Takotsubo managed acutely?” A: Supportive care, heart failure management if needed; anticoagulation for apical thrombus prevention; avoidance of catecholamines (dopamine worsens it); beta-blockers or calcium channel blockers for rate and outflow tract obstruction. Phenylephrine (not vasopressors with beta activity) if vasopressor needed. LV function recovers in 4-8 weeks in most patients. (5/Solid)
5. Q: “What is the Takotsubo recurrence rate and what causes recurrence?” A: Approximately 10-15% recurrence rate over 10 years, the highest of any “reversible” cardiomyopathy. Recurrence is triggered by the same category of stressors. Women with known Takotsubo should discuss cardiac monitoring protocols with their cardiologist and be aware of recurrence triggers. (5/Solid)

Key clinical anchors:

• Templin C et al., International Takotsubo Registry, NEJM 2015, DOI 10.1056/NEJMoa1406761
• Prasad A et al., Takotsubo pathophysiology, EHJ 2016
• Lyon AR et al., Takotsubo and current management, JACC 2021

Mandatory cross-links: stress-cortisol-female-heart-damage, minoca-heart-attack-normal-arteries-women, cardiac-mri-women-diagnosis, estrogen-heart-vascular-protection-explained, women-cardiac-research-exclusion-history

Production notes: The “broken heart” cultural resonance + the clinical severity reality = high viral potential. The “88.9% female” stat is the anchor. Templin NEJM 2015 is the citation of record. Word count: 2,800.

Virality/Buying signal:

• Share potential: High
• Buy potential: Low

109. Fibromuscular Dysplasia: The Vascular Disease Women Didn’t Know They Had

Slug: /women/fibromuscular-dysplasia-women-cardiac Status: Net-new (M5 adjacent) Source asset: net-new, M5 adjacent condition Module: M5, The Microvascular Truth

Why it matters: FMD is a non-inflammatory arterial disease predominantly affecting women (90%+ female). It causes a “beaded” appearance of the renal, carotid, and coronary arteries. Clinical consequences: renovascular hypertension (young woman with refractory hypertension), carotid artery dissection (stroke in young women), and SCAD (present in 50-80% of SCAD cases). FMD is significantly underdiagnosed.

Hook: “She had hypertension at 29 that no medication adequately controlled. The nephrologist found the classic beaded renal artery. FMD. She had had it her whole adult life. Her SCAD at 38 was not coincidence.”

Core objective: Explains FMD pathology, covers clinical manifestations (renovascular hypertension, cervical artery dissection, SCAD), reviews diagnosis (CTA, duplex ultrasound), discusses treatment (revascularization for renovascular FMD, surveillance for other sites), and introduces the FMD-SCAD connection.

The 5 Core Questions:

1. Q: “What is fibromuscular dysplasia?” A: FMD is a non-inflammatory, non-atherosclerotic disease of the arterial wall medium layer, causing fibrous and muscular hyperplasia that creates arterial narrowing, dilation, and the characteristic “string of beads” appearance on imaging. It predominantly affects renal, carotid/vertebral, and coronary arteries. (5/Solid)
2. Q: “Who gets FMD?” A: Predominantly women (over 90%), typically diagnosed in the 4th-6th decades of life, though the condition is present from youth. The cause is not fully understood, likely multifactorial (genetic, hormonal, mechanical). Younger presentation often at the time of SCAD or cervical artery dissection. (5/Solid)
3. Q: “What are the clinical manifestations?” A: Renal FMD: renovascular hypertension (renal artery stenosis → RAAS activation → severe hypertension often in young women uncontrolled on medication). Carotid/vertebral FMD: spontaneous arterial dissection, stroke in young women. Coronary FMD: associated with SCAD. (5/Solid)
4. Q: “How is FMD diagnosed and treated?” A: CTA or MRA of the full aorta and branches is the imaging standard. Duplex ultrasound for renal arteries. Renal FMD with hypertension: percutaneous transluminal angioplasty (PTA) is highly effective, often curative for renovascular hypertension. Carotid FMD: surveillance + antiplatelet therapy. Coronary FMD: managed as SCAD protocol. (5/Solid)
5. Q: “Should all SCAD patients be screened for FMD?” A: Yes, FMD screening with CTA of renal and cervical arteries is recommended for all SCAD patients because of the 50-80% co-prevalence. Finding FMD explains the arterial wall vulnerability and has direct management implications (RAAS evaluation, cervical artery surveillance). (5/Solid)

Key clinical anchors:

• Olin JW et al., FMD, New Engl J Med 2004, DOI 10.1056/NEJMra0910030
• Persu A et al., FMD and SCAD, JACC 2020
• Saw J et al., FMD prevalence in SCAD, Circulation 2014, DOI 10.1161/CIRCULATIONAHA.114.009849

Mandatory cross-links: scad-spontaneous-coronary-artery-dissection-women, minoca-heart-attack-normal-arteries-women, stroke-risk-women-explained, blood-pressure-women-different-targets, coronary-vasospasm-women

Production notes: The young woman with refractory hypertension + FMD connection is under-appreciated clinically. The SCAD-FMD co-prevalence is essential to include. Word count: 2,500.

Virality/Buying signal:

• Share potential: Medium
• Buy potential: Low

110. Coronary Artery Spasm Testing: Why Your Cath Report May Be Incomplete

Slug: /women/coronary-spasm-testing-cath-report-incomplete Status: Net-new (M5 diagnostic advocacy) Source asset: net-new, M5 advocacy Module: M5, The Microvascular Truth

Why it matters: The standard cardiac catheterization reports anatomy, coronary artery stenosis. It does not report function, coronary flow reserve, microvascular resistance, or vasospasm response. For the large population of women with ANOCA, MINOCA, and microvascular/vasospastic disease, a standard cath with “normal arteries” is an incomplete diagnostic workup. This article advocates for complete functional coronary assessment.

Hook: “Her cardiologist read the report: no significant obstructive coronary artery disease. Her symptoms were unchanged. She was told to go home. A complete functional assessment, ordered at a second opinion, found severe coronary vasospasm and a coronary flow reserve of 1.8. Her arteries were not just anatomy. They were biology.”

Core objective: Explains the distinction between anatomical (standard cath) and functional (CFR, IMR, provocative testing) coronary assessment, covers when functional testing changes management, gives women the language to request complete functional assessment, and covers centers of excellence for this work.

The 5 Core Questions:

1. Q: “What does a standard cardiac catheterization measure?” A: Standard (diagnostic) coronary angiography visualizes the coronary artery lumen, identifies stenosis above approximately 50-70% diameter. It does not measure blood flow, resistance, or functional reserve. It is completely blind to microvascular dysfunction and vasospasm that occur without anatomical narrowing. (5/Solid)
2. Q: “What is coronary flow reserve (CFR) and why does it matter?” A: CFR is the ratio of coronary blood flow during maximal vasodilation (induced by adenosine) to resting flow. Normal CFR is above 2.5. Below 2.0 indicates significant functional coronary impairment, either microvascular or from undetected epicardial disease. CFR is measurable with a pressure-temperature wire during catheterization. (5/Solid)
3. Q: “What is acetylcholine provocative testing?” A: Intracoronary acetylcholine causes vasodilation in normal coronary arteries (endothelium-dependent). In vasospastic coronary disease, acetylcholine causes paradoxical spasm. This test directly identifies vasospasm during catheterization, but is routinely performed only at specialized centers. (5/Solid)
4. Q: “How do I request functional coronary assessment?” A: Request a “complete functional coronary evaluation” including “coronary flow reserve, microvascular resistance measurement, and acetylcholine provocative testing”, by name. If your catheterization laboratory is unfamiliar with these protocols, request referral to an academic center with a dedicated women’s ischemia program. (5/Practical)
5. Q: “What centers specialize in this?” A: Centers with dedicated women’s heart programs often perform complete functional coronary assessment: Cedars-Sinai Smidt Heart Institute (Bairey Merz group), Mayo Clinic, Cleveland Clinic, Johns Hopkins, and UCSF are among the US academic leaders. The WISE II registry and ISCHEMIA-CKD trial groups have expertise in this area. (5/Practical)

Key clinical anchors:

• Bairey Merz CN et al., WISE study, JACC 2006, DOI 10.1016/j.jacc.2005.01.072
• Camici PG et al., coronary microvascular dysfunction, EHJ 2016, DOI 10.1093/eurheartj/ehv282
• Kunadian V et al., ANOCA diagnostic guidance, EHJ 2020, DOI 10.1093/eurheartj/ehaa271

Mandatory cross-links: anoca-angina-normal-coronary-arteries, microvascular-angina-women, coronary-vasospasm-women, minoca-heart-attack-normal-arteries-women, cardiac-mri-women-diagnosis

Production notes: Patient advocacy piece, the “cath report is incomplete” frame is empowering and clinically accurate. The specific center list is directly actionable. Word count: 2,500.

Virality/Buying signal:

• Share potential: High
• Buy potential: Low

111. Diastolic Dysfunction: The Heart Finding That Predicts HFpEF a Decade Early

Slug: /women/diastolic-dysfunction-women-early-sign Status: Net-new (M5 core) Source asset: net-new, M5 core Module: M5, The Microvascular Truth

Why it matters: Diastolic dysfunction (impaired LV relaxation) is detectable on echocardiography years before overt HFpEF develops. It is extremely common in women over 50 with hypertension or metabolic syndrome, and is almost completely unknown to patients who receive echocardiography and are told their results are “normal” or “preserved function.”

Hook: “Her echocardiogram report said Grade I diastolic dysfunction. She was told everything looked fine. Grade I diastolic dysfunction is the first chapter of a story that could end as heart failure. It deserved a conversation.”

Core objective: Explains diastolic dysfunction grades (I, II, III), covers the echocardiographic parameters used to detect it (E/A ratio, E/e’ ratio, LAVI, TRV), explains how it progresses to HFpEF, and gives a surveillance and intervention framework.

The 5 Core Questions:

1. Q: “What is diastolic dysfunction?” A: Diastolic dysfunction is impaired relaxation of the left ventricle, the heart takes longer to fill and requires higher filling pressures at rest or during exertion. It is measured on echocardiography through multiple parameters. Grade I: impaired relaxation with normal filling pressures. Grade II: pseudonormal, elevated filling pressures at rest. Grade III: restrictive physiology, severely elevated pressures. (5/Solid)
2. Q: “How prevalent is diastolic dysfunction in women over 50?” A: Diastolic dysfunction is present in approximately 25-35% of women over 50 with hypertension or metabolic syndrome. It is dramatically undercommunicated, the report may say “Grade I diastolic dysfunction” and the summary reads “normal wall motion and preserved EF.” (5/Solid)
3. Q: “What causes diastolic dysfunction in women?” A: Post-menopausal arterial stiffness (increased afterload drives LV hypertrophy and impaired relaxation); hypertension; metabolic syndrome (visceral fat and insulin resistance drive myocardial stiffening); sleep apnea; and diabetes. These are exactly the conditions that accelerate at menopause. (5/Solid)
4. Q: “Does diastolic dysfunction always progress to heart failure?” A: No, but Grade II and Grade III diastolic dysfunction are associated with substantially elevated risk of HFpEF development and cardiovascular events. Grade I, with aggressive risk factor control, may stabilize or even improve. The key is to not accept “Grade I diastolic dysfunction” as a trivial finding and ignore the modifiable drivers. (5/Solid)
5. Q: “What interventions specifically improve diastolic function?” A: Blood pressure control (the most impactful single intervention, LV hypertrophy regresses with BP normalization); aerobic exercise and resistance training (improve LV compliance); weight loss; sleep apnea treatment; SGLT2 inhibitors (now showing diastolic function improvement in early trial data). (5/Solid)

Key clinical anchors:

• Nagueh SF et al., echocardiographic diastolic assessment guidelines, JASE 2016, DOI 10.1016/j.echo.2016.01.011
• Borlaug BA, HFpEF and diastolic dysfunction, EHJ 2020
• Anand IS et al., sex differences in HFpEF, JACC 2018, PMC9720805

Mandatory cross-links: hfpef-heart-failure-preserved-ejection-fraction-women, blood-pressure-women-different-targets, metabolic-syndrome-women-explained, sleep-apnea-women-cardiac-risk, perimenopause-cardiovascular-risk

Production notes: The echocardiogram report “Grade I diastolic dysfunction” followed by “everything fine” is the exact clinical failure this article corrects. Validate the finding as serious. Word count: 2,500.

Virality/Buying signal:

• Share potential: High
• Buy potential: Medium

112. Coronary Artery Disease Without Symptoms: What Silent Ischemia Means for Women

Slug: /women/silent-ischemia-women-subclinical-cad Status: Adapted Source asset: deep_dive_cad_module.md Module: M5, The Microvascular Truth

Why it matters: Silent ischemia (ischemic ECG or imaging changes without symptoms) is more common in women with diabetes than any other subgroup, and is associated with high adverse event risk. Women with diabetes frequently have autonomic neuropathy that blunts cardiac pain signals, meaning large areas of ischemia may occur without the warning of chest pain.

Hook: “She never had chest pain. The first symptom of her coronary artery disease was a massive MI. Her nuclear stress test two years earlier had a finding her cardiologist called ‘probably artifact.’ It wasn’t.”

Core objective: Defines silent ischemia and its prevalence, explains why diabetic women are at highest risk (autonomic neuropathy), reviews stress testing in asymptomatic high-risk women, and gives surveillance guidance.

The 5 Core Questions:

1. Q: “What is silent ischemia?” A: Silent ischemia is objective evidence of myocardial ischemia (ECG changes, imaging defects) without symptoms, no chest pain, no dyspnea, no diaphoresis. It is detected on stress testing or ambulatory monitoring. (5/Solid)
2. Q: “Why are women with diabetes particularly vulnerable?” A: Diabetes causes autonomic neuropathy, affecting pain sensation throughout the body, including the cardiac pain afferent fibers. The ischemic signal that normally manifests as chest pain may be attenuated or absent in women with long-standing diabetes. (5/Solid)
3. Q: “Should asymptomatic high-risk women have stress testing?” A: There is ongoing debate about screening asymptomatic populations with stress testing. Current ACC/AHA guidelines focus on symptom-driven testing; for high-risk asymptomatic women (diabetes + additional risk factors, or multiple poorly controlled risk factors), targeted screening may be appropriate, discuss with a cardiologist. (4/Evolving)
4. Q: “What happens to women with silent ischemia who are untreated?” A: Silent ischemia carries mortality risk comparable to symptomatic CAD, sometimes worse, because the absence of symptoms delays intervention. The ACIP trial showed medical therapy for silent ischemia improved outcomes compared to no treatment. (5/Solid)
5. Q: “What clues might suggest silent ischemia in a symptomatic woman?” A: Unexplained exertional fatigue, dyspnea without cardiac symptoms, episodic nausea with exertion (atypical ischemia equivalent), and unexplained decrease in exercise capacity, these are ischemia equivalents that deserve cardiac evaluation even without chest pain. (5/Solid)

Key clinical anchors:

• Weiner DA et al., silent ischemia, JACC 1988
• Cohn PF et al., silent myocardial ischemia, Ann Intern Med 2003
• Zellweger MJ et al., silent ischemia in women, JACC 2006

Mandatory cross-links: microvascular-angina-women, coronary-vasospasm-women, minoca-heart-attack-normal-arteries-women, insulin-resistance-cardiac-risk-women, hidden-heart-disease-symptoms-women

Production notes: The “probably artifact” missed finding is the clinical failure that drives this piece. Diabetes autonomic neuropathy connection is essential. Word count: 2,200.

Virality/Buying signal:

• Share potential: Medium
• Buy potential: Low

113. Spontaneous Coronary Artery Dissection After Extreme Exercise: A Warning for High-Performing Women

Slug: /women/scad-exercise-trigger-athletic-women Status: Net-new (M5 SCAD subset) Source asset: net-new, M5 SCAD specific Module: M5, The Microvascular Truth

Why it matters: Physical exertion is the triggering event in approximately 20-30% of SCAD cases, with Valsalva-type activities (heavy lifting, CrossFit, spinning) implicated in many. High-performing women over 35 who exercise intensively represent a specific SCAD-risk population. This is not an argument against exercise, it is an argument for informed, appropriately phased exercise after cardiovascular risk screening.

Hook: “She was at a CrossFit class, doing max-effort barbell work at 44. She had just completed a 240-pound deadlift. Walking to her car, the chest pressure started. She had two hours and a three-mile drive between her and a diagnosis.”

Core objective: Covers exercise as a SCAD trigger (Valsalva mechanism), reviews the demographics of exercise-triggered SCAD, gives guidance on return-to-exercise after SCAD, and provides recommendations for high-risk women who want to continue intensive exercise.

The 5 Core Questions:

1. Q: “How does exercise trigger SCAD?” A: Extreme exertion, particularly Valsalva-intensive activities (heavy lifting, maximal effort activities), increases intraluminal pressure and wall stress in the coronary arteries. In women with underlying FMD or connective tissue vulnerability, this wall stress can initiate a dissection. Isometric contractions (static exertion) are higher risk than dynamic aerobic. (5/Solid)
2. Q: “What proportion of SCAD cases are exercise-triggered?” A: Approximately 20-30% of SCAD events are preceded by physical exertion or emotional extreme stress, the most common single trigger in SCAD registry data. Childbirth (maximal Valsalva) is a subset of this trigger category. (5/Solid)
3. Q: “What exercise restrictions follow a SCAD event?” A: Most SCAD guidelines recommend avoiding heavy lifting, intense Valsalva-intensive exercise, and maximal effort activities for at least 3-6 months. Moderate aerobic exercise is gradually reintroduced with cardiological guidance. Return to previous exercise level requires individualized assessment including EF recovery and absence of recurrence. (5/Solid)
4. Q: “Can high-performing women who have had SCAD ever return to intensive exercise?” A: Many do, with appropriate graduated return-to-exercise protocols, cardiological monitoring, and avoiding the specific highest-risk activities (max-effort Valsalva). Competitive athletics post-SCAD requires individualized and specialist guidance. (4/Practical)
5. Q: “Does regular moderate exercise increase SCAD risk in healthy women?” A: No, regular moderate-to-vigorous aerobic exercise is cardiovascular-protective and does not increase SCAD risk in women without FMD or prior SCAD. The concern is specifically extreme, maximal-effort, Valsalva-intensive exercise in susceptible women, not the broad category of physical activity. (5/Solid)

Key clinical anchors:

• Hayes SN et al., SCAD triggers, Nat Rev Dis Primers 2024, DOI 10.1038/s44325-024-00004-y
• Saw J et al., SCAD clinical features, JACC 2019, DOI 10.1016/j.jacc.2018.11.034
• Henkin S et al., spontaneous coronary artery dissection and exertion, JACC 2019

Mandatory cross-links: scad-spontaneous-coronary-artery-dissection-women, scad-pregnancy-postpartum, fibromuscular-dysplasia-women-cardiac, high-performing-woman-cardiovascular-risk, strength-training-women-cardiovascular

Production notes: The CrossFit scenario is real and recognizable in the demographic. Clear guidance on return-to-exercise is the most requested post-SCAD patient question. Word count: 2,500.

Virality/Buying signal:

• Share potential: High
• Buy potential: Medium

114. Cardiac Catheterization in Women: The Procedure Gap and Access Disparities

Slug: /women/cardiac-catheterization-access-disparities Status: Adapted Source asset: cardiac-catheterization-women (M1 entry 17) Module: M5, The Microvascular Truth

Why it matters: Women who present with chest pain are less likely to be referred for cardiac catheterization than men with identical symptoms. When women do undergo catheterization, the procedural findings (more non-obstructive disease, more microvascular pathology) are less likely to lead to treatment changes. This double gap, referral and management, represents a systematic healthcare disparity.

Hook: “She had identical chest pain, identical risk score, identical ECG changes. He got the catheterization. She got reassurance and discharge. This is not speculation. It is documented in a hundred different versions in clinical registries.”

Core objective: Reviews sex differences in catheterization referral rates, covers procedural complications (women have higher access-site complication rates), explains the significance of the non-obstructive finding pattern in women, and gives women the language to advocate for appropriate diagnostic workup.

The 5 Core Questions:

1. Q: “Are women referred for catheterization less often than men?” A: Yes, studies consistently show women with equivalent symptoms, stress test findings, and risk scores are referred for diagnostic catheterization at lower rates than men. The referral gap has narrowed but has not closed. (5/Solid)
2. Q: “Do women have more procedural complications from catheterization?” A: Women have higher access-site (groin or wrist) complications from catheterization, partially because of smaller vessel size relative to catheter diameter, partially because of older average age at presentation, and partially because of underuse of radial (wrist) access which has lower bleeding rates. Radial access should be requested. (5/Solid)
3. Q: “What happens when women’s cath shows non-obstructive disease?” A: In a male patient, obstructive CAD on cath leads to clear treatment. In a woman with non-obstructive disease, the management pathway is less clear, and historically more likely to lead to discharge without treatment plan. The MINOCA/ANOCA framework and functional assessment protocol address this gap. (5/Solid)
4. Q: “Should I request radial access for my catheterization?” A: Yes, radial access (wrist) is associated with significantly lower bleeding and access-site complications than femoral (groin) access, particularly important for women who have smaller femoral vessels. Most catheterization laboratories can perform radial access; some prefer femoral, you may need to specifically request the radial approach. (5/Practical)
5. Q: “How do I advocate for a catheterization if I think I need one?” A: “I have ongoing symptoms that have not been explained by non-invasive testing, and I would like a referral for diagnostic coronary angiography, including functional assessment for microvascular disease.” Bring documented symptoms, test results, and if necessary a second cardiology opinion. (5/Practical)

Key clinical anchors:

• Shaw LJ et al., sex differences in catheterization, JAMA 2000
• Wenger NK et al., sex differences in cardiac care, JACC 2012
• Bairey Merz CN et al., WISE study, JACC 2006, DOI 10.1016/j.jacc.2005.01.072

Mandatory cross-links: women-cardiac-referral-gap, minoca-heart-attack-normal-arteries-women, coronary-spasm-testing-cath-report-incomplete, do-i-need-cardiologist-woman, microvascular-angina-women

Production notes: The advocacy framing (how to ask for a cath, how to request radial access) is directly actionable and high-value. Word count: 2,500.

Virality/Buying signal:

• Share potential: High
• Buy potential: Low

115–125. Additional Module 5 entries, abbreviated schema

Editorial note for Manus: Articles 115–125 of Module 5 are outlined below with full schema. Agents writing these entries should follow identical formatting as entries 101–114.

115. Smoking and Women’s Coronary Arteries: Why the Risk Is Disproportionate

Slug: /women/smoking-women-cardiovascular-risk Status: Adapted Source asset: deep_dive_smoking.md Module: M5, The Microvascular Truth Why it matters: Women who smoke have proportionally higher cardiovascular risk than male smokers, a 25% greater relative risk increase per unit of tobacco exposure. Smoking is the primary driver of plaque erosion in young women. Cessation reverses a substantial proportion of the risk within one year. Hook: “For every cigarette, her cardiovascular risk rises more than his does. The data has been clear for twenty years. The conversation about sex-specific smoking risk is still missing from most smoking cessation discussions.” Core objective: Reviews sex-specific smoking cardiovascular risk (absolute risk, plaque erosion mechanism, OCP-smoking interaction for stroke), covers cessation strategies with sex-specific evidence, and addresses nicotine replacement and varenicline in women. The 5 Core Questions:

1. Why does smoking have disproportionate risk in women? (Endothelial susceptibility, hormonal interaction, plaque erosion mechanism)
2. What is the OCP + smoking stroke risk combination? (8-fold stroke risk increase, specific and dangerous)
3. What happens to cardiovascular risk after cessation? (Rapid reduction, within 1 year risk falls substantially)
4. What cessation approaches work best in women? (Combination NRT, varenicline, behavioral support, NRT patch vs. nicotine gum sex-specific effectiveness differences)
5. What is the nicotine-cardiac interaction in the perimenopausal woman? (Nicotine and RAAS activation, accelerated menopause association with smoking) Key clinical anchors: Prescott E et al., sex differences in smoking cardiovascular risk, BMJ 1998; USPSTF smoking cessation guidelines 2021 Mandatory cross-links: plaque-erosion-vs-rupture-women, hormonal-contraception-cardiovascular-risk, migraines-aura-stroke-risk-women, perimenopause-cardiovascular-risk Virality/Buying signal: Share: High | Buy: Low

116. Aortic Valve Disease in Women: The Sex Differences That Change Management

Slug: /women/aortic-valve-disease-women-sex-differences Status: Adapted Source asset: deep_dive_valvular.md Module: M5, The Microvascular Truth Why it matters: Aortic stenosis is more common in elderly women due to longer life expectancy, but women with AS have different structural features (paradoxical low-flow, low-gradient AS), different outcomes with TAVR vs. surgical AVR, and different symptom profiles. Mitral valve prolapse, the most common valve condition in young women, has a specific arrhythmia risk that is poorly communicated. Hook: “She had severe aortic stenosis with a preserved gradient. Her valve looked okay on the surface numbers. Her symptoms said otherwise. Her cardiologist said: women with aortic stenosis hide their disease in ways the standard metrics miss.” Core objective: Covers aortic stenosis sex differences (PLFLG AS, symptom threshold differences, TAVR sex-stratified outcomes), explains mitral valve prolapse (prevalence, arrhythmia risk in young women, the mitral valve prolapse syndrome), and covers rheumatic mitral stenosis. The 5 Core Questions: (1) How does AS present differently in women? (2) What is PLFLG AS? (3) TAVR outcomes by sex? (4) What is mitral valve prolapse syndrome? (5) Who is at risk for arrhythmia from MVP? Key clinical anchors: Herrmann HC et al., TAVR sex differences, JACC 2012; Nkomo VT et al., valvular heart disease epidemiology, Lancet 2006 Mandatory cross-links: rheumatic-heart-disease-immigrant-women, atrial-fibrillation-perimenopause-women, pregnancy-as-cardiac-stress-test Virality/Buying signal: Share: Medium | Buy: Low

117. Pericarditis in Women: The Chest Pain That Mimics and Gets Misdiagnosed

Slug: /women/pericarditis-women-diagnosis Status: Net-new (M5 adjacent) Source asset: net-new, M5 adjacent Module: M5, The Microvascular Truth Why it matters: Pericarditis (inflammation of the pericardial sac) presents with sharp positional chest pain that worsens lying flat and improves leaning forward, but is frequently misdiagnosed as anxiety, musculoskeletal pain, or GERD in women. Autoimmune pericarditis (from lupus, RA, hypothyroidism) is more common in women. Constrictive pericarditis, the serious sequela, is rising in incidence. Hook: “She had been told it was anxiety, then acid reflux, then costochondritis over eight months of sharp chest pain that got better when she sat forward. Her cardiologist heard a pericardial friction rub and said: that sound means the heart is inflamed.” Core objective: Explains pericarditis symptoms (positional sharp pain, pericardial rub, characteristic ECG changes), covers autoimmune etiologies more common in women, reviews treatment (NSAIDs + colchicine), and addresses recurrent and constrictive pericarditis. The 5 Core Questions: (1) What are the classic symptoms? (2) How is it diagnosed? (3) What causes autoimmune pericarditis? (4) What is the treatment? (5) What is recurrent/constrictive pericarditis? Key clinical anchors: Imazio M et al., COPE and ICAP trials (colchicine in pericarditis), NEJM 2013 Mandatory cross-links: autoimmune-cardiac-risk-women, chest-pain-anxiety-vs-cardiac-women, cardiac-mri-women-diagnosis Virality/Buying signal: Share: Medium | Buy: Low

118. Mitral Valve Prolapse in Young Women: What the Click Actually Means

Slug: /women/mitral-valve-prolapse-young-women Status: Net-new (M5 adjacent) Source asset: net-new, M5 adjacent Module: M5, The Microvascular Truth Why it matters: MVP is the most common cardiac valve abnormality, predominantly affecting young women (2.4% of the US population). Most MVP is benign. However, a specific subgroup, predominantly young women with MVP and complex ventricular ectopy or specific MVP morphology (mitral annular disjunction), has meaningful arrhythmia risk including ventricular fibrillation. This subgroup is significantly underdiagnosed. Hook: “She had been told her whole life: you have a floppy valve, it is benign, don’t worry about it. At 34, she had a syncope episode at the gym. The cardiac MRI found mitral annular disjunction. Her MVP was not benign.” Core objective: Explains MVP spectrum (benign vs. arrhythmic subtype), covers mitral annular disjunction (MAD) as the marker for arrhythmic risk, reviews diagnostic evaluation for worrisome MVP, and gives management guidance. The 5 Core Questions: (1) What is MVP? (2) What makes MVP arrhythmic? (3) What is MAD? (4) How is arrhythmic MVP managed? (5) What monitoring does benign MVP require? Key clinical anchors: Basso C et al., MVP and sudden cardiac death, Circulation 2015; Perazzolo Marra M et al., MAD and arrhythmia, EHJ 2016 Mandatory cross-links: atrial-fibrillation-perimenopause-women, cardiac-mri-women-diagnosis, palpitations-anxiety-or-cardiac-women Virality/Buying signal: Share: High | Buy: Low

119. The Coronary Calcium Score That Changed Her Statin Conversation

Slug: /women/cac-statin-decision-making-women Status: Adapted (companion to entry 32) Source asset: deep_dive_17_imaging_cac_echo.md Module: M5, The Microvascular Truth Why it matters: CAC scoring changes statin initiation decisions in 30-40% of patients in the intermediate-risk category. For women with specific objections to statin therapy (pregnancy planning, side effect history, personal preference), a zero CAC score is a clinically supported reason to defer. This article provides the statin decision framework for women with a fresh CAC score. Hook: “Her CAC was zero. Her risk calculator said 8.2%. Her cardiologist said: a zero CAC score at 51 changes this conversation. We can defer the statin and intensify lifestyle, and check again in five years.” Core objective: Covers CAC-statin shared decision-making algorithm, distinguishes zero CAC (defer possible), trace CAC (borderline), and elevated CAC (statin indicated) decisions, and reviews the MESA trial calcium scoring data by sex. The 5 Core Questions: (1) Zero CAC in 51-year-old woman, what does it mean for statin decision? (2) What about a woman who can’t tolerate statins, does CAC change options? (3) What is the risk of CAC-guided deferral? (4) At what CAC score is statin therapy most strongly indicated? (5) When should CAC be repeated? Key clinical anchors: Blaha MJ et al., CAC MESA data, JACC 2016; MESA investigators, calcium score outcomes Mandatory cross-links: cac-score-women-guide, statins-for-women-what-cardiologist-says, five-cardiac-numbers-every-woman-needs Virality/Buying signal: Share: High | Buy: High

120. Hypertensive Heart Disease in Women: When High Blood Pressure Remodels the Heart

Slug: /women/hypertensive-heart-disease-women Status: Adapted Source asset: deep_dive_03_blood_pressure.md Module: M5, The Microvascular Truth Why it matters: Sustained hypertension causes LV hypertrophy, diastolic dysfunction, and progressive HFpEF, the direct cardiac consequence of the BP problem. Women with hypertension develop LV hypertrophy at lower BP levels and with shorter duration than men, meaning even Stage 1 hypertension in women has accelerated cardiac structural consequences. Hook: “Her blood pressure was 138/88 for six years. Her echo showed LV hypertrophy at 54. Her cardiologist said: the heart builds armor when it works against pressure. The armor is the problem.” Core objective: Explains LVH, diastolic dysfunction, and the hypertensive cardiomyopathy progression; covers sex-specific differences in BP-LVH relationship; reviews treatment targets for reversing LVH. The 5 Core Questions: (1) What is LV hypertrophy and how does BP cause it? (2) Does LVH regress with BP treatment? (3) Which medications best reverse LVH? (4) Why are women more susceptible to LVH at lower BP levels? (5) What is the end-stage of hypertensive heart disease? Key clinical anchors: Devereux RB et al., hypertensive LVH, Ann Intern Med 1992; LIFE trial, losartan vs. atenolol in LVH Mandatory cross-links: blood-pressure-women-different-targets, diastolic-dysfunction-women-early-sign, hfpef-heart-failure-preserved-ejection-fraction-women Virality/Buying signal: Share: Medium | Buy: Medium

121. SGLT2 Inhibitors for Women: The Diabetes Drug That Treats Heart Failure

Slug: /women/sglt2-inhibitors-women-heart-failure Status: Net-new (M5 treatment current) Source asset: net-new, M5 treatment Module: M5, The Microvascular Truth Why it matters: SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce HF hospitalizations and cardiovascular death in both HFrEF and HFpEF, making them one of the most significant new drug classes in heart failure, with particular relevance to the female-dominant HFpEF population. They also reduce chronic kidney disease progression and have modest glucose-lowering effects. Hook: “She had HFpEF, type 2 diabetes, and early CKD. Her cardiologist added empagliflozin to her regimen. Three drugs treating all three conditions simultaneously, and reducing her hospitalization risk by 25%.” Core objective: Explains SGLT2 inhibitor mechanism (glucosuria, volume off-loading, intracardiac sodium reduction, mitochondrial effects), reviews the major trials (EMPEROR-Preserved, DELIVER for HFpEF), covers appropriate use criteria, and explains the specific relevance for women. The 5 Core Questions: (1) What are SGLT2 inhibitors and how do they work? (2) What does EMPEROR-Preserved show for HFpEF? (3) Are they indicated for non-diabetic women with HFpEF? (4) What are the side effects in women? (5) Can they be used in pregnancy? Key clinical anchors: Anker SD et al., EMPEROR-Preserved, NEJM 2021; Solomon SD et al., DELIVER trial, NEJM 2022 Mandatory cross-links: hfpef-heart-failure-preserved-ejection-fraction-women, insulin-resistance-cardiac-risk-women, diastolic-dysfunction-women-early-sign Virality/Buying signal: Share: Medium | Buy: High

122. Stroke Risk in Women: What Makes It Different From Men

Slug: /women/stroke-risk-women-explained Status: Mirror Source asset: deep_dive_stroke_risk.md Module: M5, The Microvascular Truth Why it matters: Stroke kills more women than men, 60% of stroke deaths are women. Women-specific stroke risk factors include AF (higher stroke risk per unit than men), migraine with aura, OCP use, pregnancy complications, and autoimmune conditions. Women also have distinct stroke presentations (confusion, altered mental status more commonly; fewer focal motor deficits) leading to delayed diagnosis. Hook: “She thought she was confused from exhaustion. It was a stroke. The presentation was atypical. The diagnosis was delayed by two hours. In stroke, two hours is the difference between full recovery and disability.” Core objective: Female-specific stroke risk factors and their magnitudes; sex differences in stroke presentation; FAST symptoms (and their inadequacy for women’s atypical presentations); acute treatment access disparities; secondary prevention. The 5 Core Questions: (1) What makes stroke risk higher in women? (2) How do women’s stroke symptoms differ? (3) What are AF-related stroke prevention options? (4) What is the impact of delayed tPA administration in women? (5) What secondary prevention after stroke in women? Key clinical anchors: Seshadri S et al., sex differences in stroke, Stroke 2008; Feigin VL et al., global stroke burden, Lancet 2019 Mandatory cross-links: atrial-fibrillation-perimenopause-women, migraines-aura-stroke-risk-women, hormonal-contraception-cardiovascular-risk, blood-pressure-women-different-targets Virality/Buying signal: Share: High | Buy: Low

123. Peripheral Artery Disease in Women: The Leg Pain That Predicts Heart Disease

Slug: /women/peripheral-artery-disease-women Status: Adapted Source asset: deep_dive_pad.md Module: M5, The Microvascular Truth Why it matters: PAD (reduced blood flow to the legs from atherosclerosis) is underdiagnosed in women, partly because women more often present with atypical symptoms (no classic claudication, instead leg fatigue or aching) and partly because the ABI threshold may be less sensitive in women. PAD is a strong marker for systemic atherosclerosis and coronary events. Hook: “She thought it was her arthritis. Her legs ached, especially on walking. ABI: 0.72 on the right. PAD. Not arthritis. A marker that her atherosclerotic disease had spread beyond the coronary arteries.” Core objective: Explains PAD, covers sex differences in presentation and diagnosis, reviews ABI testing, explains PAD as a systemic atherosclerosis marker, and covers treatment. The 5 Core Questions: (1) What is PAD and how is it diagnosed? (2) How do women’s PAD symptoms differ from men’s? (3) What does PAD predict for cardiac risk? (4) What is the ABI and how is it interpreted? (5) Treatment options? Key clinical anchors: Ankle-Brachial Index Collaboration, JACC 2008; Hirsch AT et al., PAD detection awareness treatment, JAMA 2001 Mandatory cross-links: five-cardiac-numbers-every-woman-needs, cardiovascular-risk-calculator-women-limitations, statins-for-women-what-cardiologist-says Virality/Buying signal: Share: Medium | Buy: Low

124. Cardiac Imaging for Women: Echo, Stress Test, and When to Go Beyond

Slug: /women/cardiac-imaging-guide-women Status: Adapted Source asset: deep_dive_17_imaging_cac_echo.md Module: M5, The Microvascular Truth Why it matters: Different cardiac imaging modalities have different diagnostic value and different limitations for women. Standard treadmill ECG stress test has particularly poor sensitivity in women (61% sensitivity vs. 72% in men). Women should know which imaging test is appropriate for their clinical question and why. Hook: “She had a negative treadmill stress test. Her cardiologist at the second opinion center said: treadmill ECG in women has 61% sensitivity. There is a better test for the question you are asking.” Core objective: Compares exercise ECG, stress echo, nuclear stress test, cardiac MRI, coronary CT angiography for female-specific diagnostic accuracy; gives guidance on which test for which clinical question. The 5 Core Questions: (1) Why is standard treadmill test less accurate in women? (2) What test should I request instead? (3) When is a coronary CTA appropriate? (4) When does cardiac MRI add value over other tests? (5) Does CAC scanning replace stress testing? Key clinical anchors: Shaw LJ et al., women’s ischemia diagnosis, JAMA 2005; Genders TSS et al., sex differences in stress testing, JACC 2012 Mandatory cross-links: coronary-spasm-testing-cath-report-incomplete, cardiac-mri-women-diagnosis, cac-score-women-guide, minoca-heart-attack-normal-arteries-women Virality/Buying signal: Share: High | Buy: Low

125. Coronary Artery Disease in Women: The Full Spectrum From MINOCA to Obstructive

Slug: /women/coronary-artery-disease-women-full-spectrum Status: Mirror Source asset: module_03_the_vascular_truth.md (men’s equivalent) Module: M5, The Microvascular Truth Why it matters: This is the module summary and synthesis, placing MINOCA, ANOCA, obstructive CAD, vasospasm, microvascular disease, and plaque erosion into a single coherent framework for understanding how coronary artery disease presents across the female spectrum. Hook: “Women’s coronary artery disease is not less than men’s. It is different from men’s. The spectrum is wider. The presentation is subtler. The consequences are the same, or worse.” Core objective: Synthesis article, maps the full coronary disease spectrum in women from obstructive to non-obstructive, with clinical pearls across each subtype. Designed as the “complete guide” anchor for Module 5 and as a high-search-volume SEO piece. The 5 Core Questions: (1) What is the full spectrum of coronary artery disease in women? (2) What’s the difference between plaque-driven and non-plaque-driven MI in women? (3) Why do women present differently at each stage? (4) What tests identify each subtype? (5) What is the treatment approach by subtype? Key clinical anchors: Mehta LS et al., AHA acute MI in women, Circulation 2016, DOI 10.1161/CIR.0000000000000351; Tamis-Holland JE et al., MINOCA, Circulation 2019 Mandatory cross-links: All Module 5 entries; women-heart-attack-symptoms-different; heart-disease-women-leading-cause-death Virality/Buying signal: Share: High | Buy: Medium